Dengue vaccine

Kathryn Dzintars, PharmD, BCPS
Dengue vaccine is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

VACCINE TYPE

  • Dengvaxia®, or the Dengue Tetravalent Vaccine, is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3 and 4.
    • Approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection AND who lived in an endemic area.
    • The vaccine is built on a yellow fever backbone component.

-- To view the remaining sections of this topic, please or --

VACCINE TYPE

  • Dengvaxia®, or the Dengue Tetravalent Vaccine, is a live, attenuated vaccine active against dengue virus serotypes 1, 2, 3 and 4.
    • Approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection AND who lived in an endemic area.
    • The vaccine is built on a yellow fever backbone component.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 19, 2023